Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro - PubMed (original) (raw)
Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro
Andrea Galli et al. Gastroenterology. 2002 Jun.
Abstract
Background & aims: The ligand-dependent transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma) is expressed in hepatic stellate cells (HSC), and its transcriptional activity is reduced during cell transdifferentiation in culture. PPARgamma transcriptional activation decreases platelet-derived growth factor-induced proliferation and inhibits alpha-smooth muscle actin expression in cultured HSC. The aim of our study was to evaluate whether oral administration of synthetic PPARgamma ligands, thiazolidinediones (TZD), might affect collagen deposition in animal models of liver fibrosis.
Methods: The effect of 2 TZD (pioglitazone or rosiglitazone) was tested on liver fibrosis induced in rats by either toxin administration (dimethylnitrosamine or carbon tetrachloride) or bile duct ligation. In vivo PPARgamma activation was evaluated by gel shift assay using nuclear extracts from HSC isolated from control and treated rats.
Results: Oral administration of TZD reduced extracellular matrix deposition and HSC activation in both toxic and cholestatic models of liver fibrosis. PPARgamma-specific DNA binding was significantly impaired in nuclear extracts of HSC isolated from fibrotic rats compared with HSC from control rats. TZD administration restored PPARgamma DNA binding in HSC nuclei. In vitro, TZD-induced PPARgamma activation inhibited collagen and fibronectin synthesis induced by transforming growth factor (TGF)-beta1 in human HSC, as measured by enzyme-linked immunosorbent assay and Northen blotting. TZD also reduced the TGF-beta1-induced activity of a 3.5-kilobase procollagen type I promoter transfected in human HSC.
Conclusions: These findings indicate that PPARgamma activation in HSC retards fibrosis in vivo and suggest the use of TZD for the treatment of liver fibrosis.
Similar articles
- Peroxisome proliferator-activated receptors and hepatic stellate cell activation.
Miyahara T, Schrum L, Rippe R, Xiong S, Yee HF Jr, Motomura K, Anania FA, Willson TM, Tsukamoto H. Miyahara T, et al. J Biol Chem. 2000 Nov 17;275(46):35715-22. doi: 10.1074/jbc.M006577200. J Biol Chem. 2000. PMID: 10969082 - Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells.
Galli A, Crabb D, Price D, Ceni E, Salzano R, Surrenti C, Casini A. Galli A, et al. Hepatology. 2000 Jan;31(1):101-8. doi: 10.1002/hep.510310117. Hepatology. 2000. PMID: 10613734 - Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride.
Kon K, Ikejima K, Hirose M, Yoshikawa M, Enomoto N, Kitamura T, Takei Y, Sato N. Kon K, et al. Biochem Biophys Res Commun. 2002 Feb 15;291(1):55-61. doi: 10.1006/bbrc.2002.6385. Biochem Biophys Res Commun. 2002. PMID: 11829461 - Troglitazone and related compounds: therapeutic potential beyond diabetes.
Fujiwara T, Horikoshi H. Fujiwara T, et al. Life Sci. 2000 Oct 6;67(20):2405-16. doi: 10.1016/s0024-3205(00)00829-8. Life Sci. 2000. PMID: 11065164 Review.
Cited by
- New advances in drug development for metabolic dysfunction-associated diseases and alcohol-associated liver disease.
Zhang J, Li Y, Yang L, Ma N, Qian S, Chen Y, Duan Y, Xiang X, He Y. Zhang J, et al. Cell Biosci. 2024 Jul 6;14(1):90. doi: 10.1186/s13578-024-01267-9. Cell Biosci. 2024. PMID: 38971765 Free PMC article. Review. - Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options.
Portincasa P, Khalil M, Mahdi L, Perniola V, Idone V, Graziani A, Baffy G, Di Ciaula A. Portincasa P, et al. Int J Mol Sci. 2024 May 22;25(11):5640. doi: 10.3390/ijms25115640. Int J Mol Sci. 2024. PMID: 38891828 Free PMC article. Review. - Antidiabetic, Antihyperlipidemic, and Antioxidant Evaluation of Phytosteroids from Notholirion thomsonianum (Royle) Stapf.
Huneif MA, Fahad S, Abdulwahab A, Alqahtani SM, Mahnashi MH, Nawaz A, Hussain F, Sadiq A. Huneif MA, et al. Plants (Basel). 2023 Oct 17;12(20):3591. doi: 10.3390/plants12203591. Plants (Basel). 2023. PMID: 37896054 Free PMC article. - Reduction in Obesity-Related Hepatic Fibrosis by SR1664.
McVicker BL, Simpson RL, Hamel FG, Bennett RG. McVicker BL, et al. Biology (Basel). 2023 Sep 26;12(10):1287. doi: 10.3390/biology12101287. Biology (Basel). 2023. PMID: 37886997 Free PMC article. - MAFLD: an optimal framework for understanding liver cancer phenotypes.
Crane H, Gofton C, Sharma A, George J. Crane H, et al. J Gastroenterol. 2023 Oct;58(10):947-964. doi: 10.1007/s00535-023-02021-7. Epub 2023 Jul 20. J Gastroenterol. 2023. PMID: 37470858 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical